Regeneron Pharmaceuticals (REGN) News Today

Regeneron Pharmaceuticals (NASDAQ:REGN) shares have decreased today amid a mix of encouraging clinical and regulatory updates offset by modest analyst adjustments and neutral ratings. Key developments include:

• Positive Sentiment: Cantor Fitzgerald raised its FY2025 EPS estimate for REGN to $31.81 (from $30.25), signaling stronger profit potential. Free Report
• Positive Sentiment: A Forbes analysis highlighted REGN as a value opportunity, noting shares trade nearly 44% below their one-year high and at a below-average price-to-sales multiple. Forbes
• Positive Sentiment: Regeneron and Bayer completed a long-term study on retinopathy of prematurity treatments, advancing their neonatal eye disease pipeline. TipRanks
• Positive Sentiment: A real-world safety study for aflibercept was completed, reinforcing confidence in one of REGN’s key ophthalmology drugs. TipRanks
• Positive Sentiment: Alnylam and Regeneron announced progress in a collaborative Alzheimer’s study, underscoring REGN’s neuroscience ambitions. TipRanks
• Positive Sentiment: Regeneron secured FDA approval for Libtayo in a new oncology indication, expanding its high-risk skin cancer label. Zacks
• Neutral Sentiment: Morgan Stanley trimmed its REGN price target slightly to $756 (from $761) but maintained an “overweight” rating, implying roughly 34% upside. Benzinga
• Neutral Sentiment: Weiss Ratings reaffirmed its hold (C-) rating on REGN shares. Weiss Ratings
• Neutral Sentiment: Short interest in REGN remained negligible, with a 0.0-day ratio, indicating little bearish positioning.

The stock’s pullback reflects investors balancing robust clinical and regulatory achievements against incremental target adjustments and neutral analyst stances.